Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma.

"Conflict of Interest Statement TC Yau has a consulting or advisory role for and receives honoraria from Bristol Myers Squibb, MSD, Exelixis, Ipsen, Eisai, AstraZeneca, Bayer, Novartis, EMD Serono, AbbVie, Pfizer, Eli Lilly, Sirtex, SillaJen, Taiho, OrigiMed, New B Innovation, Sirtex, and H3 Biomedicine."

"The study was supported by the Hong Kong Research Grants Council (RGC) Theme-based Research Scheme (T12-704/16-R and T12-716/22-R), Innovation and Technology Commission grant to State Key Laboratory of Liver Research, University Development Fund of the University of Hong Kong, and Loke Yew Endowed Professorship award. Nivolumab was sponsored by Bristol Myers Squibb (Investigators Initiated Study, CA209-7KU). I.O.L. Ng is Loke Yew Professor in Pathology."

"This was a single-arm, single-center study designed to assess the clinical benefit of neoadjuvant treatment with nivolumab in patients with untreated, intermediate, and locally advanced HCC. The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster and was conducted in compliance with International Conference on Harmonization Good Clinical Practice. All patients provided written informed consent. The study was registered on the ClinicalTrials.gov (study identifier: NCT05471674) and HKU Clinical Trials Registry (study identifier: HKUCTR-2807)."